Short Interest in abrdn Life Sciences Investors (NYSE:HQL) Expands By 217.9%

abrdn Life Sciences Investors (NYSE:HQL) saw a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 58,626 shares, an increase of 217.9% from the July 30th total of 18,442 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 149,213 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several hedge funds have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. increased its holdings in shares of abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after purchasing an additional 1,529 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of abrdn Life Sciences Investors by 187.8% during the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after buying an additional 4,593 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of abrdn Life Sciences Investors during the 4th quarter worth about $177,000. Evolve Private Wealth LLC bought a new stake in shares of abrdn Life Sciences Investors during the 4th quarter worth about $199,000. Finally, Independent Financial Group LLC acquired a new position in abrdn Life Sciences Investors in the 1st quarter valued at about $211,000. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Trading Down 2.6%

abrdn Life Sciences Investors stock traded down $0.57 during midday trading on Friday, reaching $20.98. 164,311 shares of the company’s stock were exchanged, compared to its average volume of 154,212. The stock’s 50-day simple moving average is $20.27 and its 200 day simple moving average is $18.21. abrdn Life Sciences Investors has a 52 week low of $13.82 and a 52 week high of $22.67.

abrdn Life Sciences Investors Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, August 24th will be issued a dividend of $0.62 per share. The ex-dividend date of this dividend is Monday, August 24th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 11.8%.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.